Since its arrival on the market, the Sputnik vaccine was met with some suspicion. The Phase III study published in the Lancet had several mistakes which were then highlighted in letters to the editors. However, the publication was never retracted, and the Sputnik vaccine was widely distributed in Latin America, Asia, and Africa.
One of the most severe side effects of the COVD 19 vaccines is the onset of very rare cases of thrombosis with thrombocytopenia syndrome, later named vaccine-induced immune thrombocytopenia and thrombosis (VITT). Estimations of the incidence of VITT range from 3.2 to 16.1 cases per million doses for the Pfizer and Astra Zeneca vaccines. The results of repeated searches of the literature indicated that no cases were reported after the administration of the Sputnik V vaccine as of August 12, 2022. This is not in agreement with the reports of aggregated data published by the Argentinian Ministry of Health.
“The possibility of VITT after the adenovirus vector Sputnik V vaccine has not been cited in regulatory warnings or by the news media. The Sputnik V vaccine has been widely distributed in 71 countries in Latin America, Asia, and Africa. Because even a very low case rate could have resulted in hundreds of cases, it is mandatory to raise public awareness and to take the necessary steps to expand early detection of VITT after the administration of the Sputnik V vaccine.”1
Click here to read more.
References
- Herrera-Comoglio, R., & Lane, S. (2022). Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine. New England Journal of Medicine, 387(15), 1431–1432. https://doi.org/10.1056/nejmc2210813
Disclaimers
- The material in these reviews is from various public open access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
